Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Daiichi Sankyo
Medtronic
Teva
Moodys

Generated: July 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,067,472

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,067,472 protect, and when does it expire?

Patent 8,067,472 protects ZOLINZA and is included in one NDA.

This patent has eighty-nine patent family members in twenty-eight countries.

Summary for Patent: 8,067,472
Title:Methods of treating Hodgkin's and non-Hodgkin's lymphoma
Abstract: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Inventor(s): Richon; Victoria M. (Rye, NY), Chiao; Judy H. (Berkeley Heights, NJ), Kelly; William Kevin (Scotch Plains, NJ), Miller; Thomas A. (Brookline, MA)
Assignee: Merck HDAC Research, LLC (Boston, MA) Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:12/799,368
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,067,472
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,067,472

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 8,067,472

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 462426 ➤ Sign Up
Australia 2003213684 ➤ Sign Up
Australia 2004266169 ➤ Sign Up
Australia 2004283717 ➤ Sign Up
Australia 2008246251 ➤ Sign Up
Australia 2009201668 ➤ Sign Up
Brazil 0308250 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Covington
Fish and Richardson
Fuji
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.